Helping To Bring Hematologic Oncology Therapies To Cancer Patients

Blood cancer trials are some of the most demanding studies to run. Protocols are complex, standards of care keep changing, and many patients have serious health conditions that complicate eligibility and treatment. Sponsors also have to manage diseases that can change form over time (such as myelodysplastic syndrome progressing to acute myeloid leukemia), specialized response measures like minimal residual disease, bridging therapy before treatments such as CAR T, and intense competition for the same patients and sites.

Worldwide Clinical Trials brings focused hematology-oncology experience to these challenges. The team has supported fast-track and accelerated approvals across 320+ sites globally, including the first FDA approval of a BCMA-directed CAR T therapy for multiple myeloma. It also works across newer treatment types such as antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors. Team members average 11+ years of oncology experience, and clinical trial retention is above 90%, so sponsors keep the same team from first-in-human studies through approval. Learn how the right expertise can help you get past enrollment hurdles and protocol complexity and move your blood cancer therapy forward faster.